

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet	1	of	1
-------	---	----	---

**Complete if Known**

Application Number	09/887,204
--------------------	------------

<b>Filing Date</b>	June 22, 2001
--------------------	---------------

First Named Inventor	M. FLASHNER-BARAK et al.
----------------------	--------------------------

<b>Art Unit</b>	<b>1615</b>
-----------------	-------------

Examiner Name	BLESSING M. FUBARA
---------------	--------------------

Attorney Docket Number	01662/53002
------------------------	-------------

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
/BF/		6,930,129	08-16-2005	Alza Corp.	
		6,348,211	02-19-2002	Noven Pharm. Inc.	
		6,344,215	02-05-2002	Eurand America Inc.	
		6,635,284	10-21-2003	Celegene Corp.	
		6,673,367	01-06-2004	Euro-Celtique, SA	
		6,919,373	07-19-2005	Alza Corp.	
		5,958,446	09-28-1999	Noven Pharm. Inc.	
		6,210,705	04-03-2001	Noven Pharm. Inc.	
		7,083,808	08-01-2006	Euro-Celtique SA	
		6,419,960	07-16-2002	Euro-Celtique SA	
		6,368,626	04-09-2002	Alza Corp.	
		6,352,721	03-05-2002	Osmotica Corp.	
		5,874,090	02-23-1999	Medeva Europe Ltd.	
		4,983,400	01-08-1991	Merck & Co, Inc.	
		5,443,843	08-22-1995	Pfizer	
		5,603,955	02-18-1997	Univ. of Cincinnati	
		6,589,549	07-08-2003	Macromed, Inc.	
		5,972,389	10-26-1999	DepoMed, Inc.	
		4,642,233	02-10-1987	Alza Corp.	
		4,717,713	01-05-1988	Research Corp.	
		2002/0044962	04-18-2002	S. Rao Cherukuri, et al.	
		2002/0044960	04-18-2002	S. Rao Cherukuri	
		2002/0035357	03-21-2002	J. Faour, et al.	
/BF/		2002/0136744	09-26-2002	Merck & Co., Inc.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
/BF/		WO 05/042101	05-12-2005	Teva Pharm. Indus. Ltd.		
/BF/		WO 96/29055	09-26-1996	The Boots Co. PLC		
/BF/		WO 92/09307	06-11-1992	Kabi Pharmacia AB		


**Examiner  
Signature**

**/Blessing Fubara/**

Date Considered

05/29/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT  
PTO-1449**

DOCKET NO.  
1662/53002

SERIAL NO  
09/887604

APPLICANT  
Moshe FLESHNER-BARAK et al.

FILING DATE  
June 22, 2001

GROUP  
1615

**RECEIVED**

**TECH CENTER 1600/2800**

**MAR 24 2003**

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
/BF/	6,271,278	August 7, 2001	Park et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS**

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

<b>EXAMINER</b> /Blessing Fubara/	<b>DATE CONSIDERED</b> 05/29/2007
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

DOCKET NO.  
1662/53002

SERIAL NO.  
09/887,204

APPLICANT  
FLESHNER-BARAK et al.

FILING DATE  
June 22, 2001

GROUP  
1615

JAN 3 0 2002

CH CENTER 1600/2900

RECEIVED

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
/BF/	2,996,431	August 15, 1961	Barry			
	3,139,383	June 30, 1964	Neville			
	3,995,058	November 30, 1976	Hammond et al.			
	4,140,755	February 20, 1979	Sheth et al.			
	4,167,558	September 11, 1979	Sheth et al.			
	4,190,672	February 26, 1980	Fahn			
	4,434,153	February 28, 1984	Urquhart et al.			
	4,557,925	December 10, 1985	Lindahl et al.			
	4,704,285	November 3, 1987	Alderman			
	4,705,651	November 10, 1987	Staibano			
	4,721,613	January 26, 1988	Urquhart et al.			
	4,752,470	June 21, 1988	Mehta			
	4,756,911	July 12, 1988	Drost et al.			
	4,758,436	July 19, 1988	Caldwell et al.			
	4,764,380	August 16, 1988	Urquhart et al.			
	4,767,627	August 30, 1988	Caldwell et al.			
	4,853,229	August 1, 1989	Theeuwes			
	4,919,938	April 24, 1990	Lovegrove et al.			
	4,983,398	January 8, 1991	Gaylord et al.			
	5,007,790	April 16, 1991	Shell			
	5,051,262	September 24, 1991	Panoz et al.			
	5,198,229	March 30, 1993	Wong et al.			
	5,232,704	August 3, 1993	Franz et al.			
	5,780,057	July 14, 1998	Conte et al.			
	5,837,284	November 17, 1998	Mehta et al.			
	5,840,756	November 24, 1998	Cohen et al.			
	6,034,101	March 7, 2000	Gupta et al.			
	6,120,803	September 19, 2000	Wong et al.			
/BF/	6,261,601	July 7, 2001	T. Gur et al.			

BEST AVAILABLE COPY



## FOREIGN PATENT DOCUMENTS

RECEIVED  
JAN 30 2002  
CENTER 1600/2900

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/BF/	H4-346919	December 2, 1992	Japan				
/BF/	WO 99/04764	February 4, 1999	WO <del>PCT</del>			X	

## OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
/BF/		Hwang, Sung-Joo; Park, Haesun; Park, Kinam, "Gastric Retentive Drug-Delivery Systems", Critical Reviews in Therapeutic Drug Carrier Systems, 1998, Volume 15, Issue 3, pages 243-284
/BF/		Chen, Jun; Park Kinam, "Synthesis and characterization of superporous hydrogel composites", Journal of Controlled Release 65, 2000, pages 73-82
/BF/		The United States Pharmacopeia and The National Formulary, January 1, 2000, 24/ 19, page 2235 (1999)
/BF/		Chen, Jun; Blevins, William E.; Park, Haesun; Park, Kinam, "Gastric retention properties of superporous hydrogel composites", Journal of Controlled Release 64, 2000, pages 39-51

EXAMINER	/Blessing Fubara/	DATE CONSIDERED	05/29/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			